HLB Genex, Inc. (187420.KQ)
KOSDAQ · KRW · Basic Materials · Specialty Chemicals
₩2,230 (+3.24%) as of
Key statistics
- Market cap
- 72.80B
- Dividend yield
- 0.00%
- 52-week range
- 1,323.00 – 3,680.00
- Beta
- 0.06
- Revenue (TTM)
- 45.67B
- Profit margin
- 20.28%
- Volume
- 98.82k
About HLB Genex, Inc.
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, oral mucositis, nonalcoholic steatohepatitis, diabetic macular edema, and dry eye indications. The company was formerly known as GenoFocus, Inc. HLB Genex, Inc. was founded in 2000 and is based in Daejeon, South Korea.
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Headquarters
- Daejeon, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.